With a strong investor syndicate providing strategic and financial support, we are focused on advancing our lead candidate (IVX-121) into the clinic. IVX-121 targets respiratory syncytial virus (RSV), a major cause of viral pneumonia for which no vaccine has been FDA approved.

Icosavax, Inc.

1616 Eastlake Avenue E. Suite 208 
Seattle, WA 98102

  • White Twitter Icon
  • White Facebook Icon
  • White LinkedIn Icon
SEND US A MESSAGE

© 2019 Icosavax, Inc. All rights reserved.